-
Health Technology Assessments of Oncology Orphan and Advanced Therapies: The Case for Incorporating Real-World Evidence Patient-Reported Outcomes and Indirect Treatment Comparisons Into Joint Clinical Assessment Submissions
Sep 9, 2025, 16:22 PM -
Evaluation of Health-Related Quality of Life (HRQoL) Among Patients Treated With Lifileucel After Progression on Immune Checkpoint Inhibitors (ICIs) and Targeted Therapies: Analyses From the C-144-01 Trial
Sep 9, 2025, 16:22 PM -
Decoding Atorvastatin-Induced Arthritis: A Systems Pharmacology Approach Integrating Pharmacovigilance, Bioinformatics, and Pathway Enrichment
Sep 9, 2025, 16:22 PM -
Exploration of the Utility of Linguistic Validation Cognitive Debriefing Interviews in Generating Evidence for Adding or Modifying Source COA Content
Sep 9, 2025, 16:22 PM -
Transition Across Cognitive States and Death Among Older Adults With Type 2 Diabetes: Determining the Predictors of Cognitive Decline With a Multistate Markov Model
Sep 9, 2025, 16:22 PM -
MIRROR KEYNOTE: Generating Real-World External Control Arms in Non-Small Cell Lung Cancer Using a Curated Database
Sep 9, 2025, 16:22 PM -
Factors Associated With Positive Cost-Effectiveness Judgments in HIRA Drug Reimbursement Decisions: An 8-year Retrospective Review
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Model of Ranolazine for Treating Chronic Stable Angina Patients From Kingdom of Saudi Arabia Perspective
Sep 9, 2025, 16:22 PM -
Payer and HTA Evaluation Criteria and Considerations for Coverage and Reimbursement of Patient Self-Monitoring Technology
Sep 9, 2025, 16:22 PM -
The Broader Economics of Chronic Spontaneous Urticaria (CSU) in Japan: Assessing Societal and Fiscal Benefits of Novel Therapies
Sep 9, 2025, 16:22 PM -
Real-World Clinical and Economic Outcomes of Time in Range in Association With Diabetic Retinopathy Among Patients With Type I Diabetes
Sep 9, 2025, 16:22 PM -
Advocating From the Margins: How Patient Input Aligns With Broader Evidence Tolerance in HTA Within Oncology
Sep 9, 2025, 16:22 PM -
Considerations for Modeling Caregiver Spillover Within Economic Evaluations for Neurological Disorders: Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), and Multiple Sclerosis (MS)
Sep 9, 2025, 16:22 PM -
Work Productivity Loss Among Caregivers of Pediatric Patients With COVID-19 OR Influenza/Influenza-Like Illness: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Utilizing the Patient-Specific Needs Evaluation for Data-Supported and Individualized Treatment (UNITE)
Sep 9, 2025, 16:22 PM -
Association of eGFR Decline and Cardiovascular Outcomes in Chronic Kidney Disease Patients: Feasibility of Frequency Matching Replicating Event-Driven Clinical Trials With Real-World Data Long-Term
Sep 9, 2025, 16:22 PM -
Patients With Lupus Across Germany: An AI/ML Driven Method to Maximize Patient Selection From Longitudinal Prescription Data (IQVIA LRx)
Sep 9, 2025, 16:22 PM -
Measuring Quality of Life in Huntington’s Disease Using a Proxy Approach: Validation of the HD-mQoL-prx Measure
Sep 9, 2025, 16:22 PM -
Effectiveness of Psychosocial Interventions for Adults With Substance Use Disorder and Co-Occurring Mental Health Disorder: An Umbrella Review
Sep 9, 2025, 16:22 PM -
Applicability of the STEDI Value Framework to Vaccines in Health Technology Assessment: Opportunities and Considerations
Sep 9, 2025, 16:22 PM
